Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-week, Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release in Children and Adolescent Subjects With Bipolar Depression

NCT00811473 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00811473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00811473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-week, Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release in Children and Adolescent Subjects With Bipolar Depression
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2009
Completion date
November 30, 2010
Enrollment
193 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar depression